|
|
|
| Changes of Immune System and Inflammatory Factors in Children with Bronchitis after Glucocorticoid Therapy |
| QIAN Tong, SUN Dan, LI Yan-yan,et al |
| XuZhou Children's Hospital,Jiangsu Xuzhou 221000 |
|
|
|
|
Abstract 【Objective】To investigate the changes and significance of T lymphocyte subsets and immunoglobulins and inflammatory factors in children with bronchitis after glucocorticoid therapy. 【Methods】A total of 80 children with bronchitis admitted to our hospital from January 2015 to August 2018 were selected as subjects. They were divided into two groups with 40 cases each according to different treatment methods. Patients in the control group received symptotherapy like anti-infective and expectorant, while patients in the observation group received symptomatic treatments based on budesonide atomization inhalation therapy.). Clinical efficacy and changes of immune system and inflammatory factors were compared between the two groups.. 【Results】The disappearing time of cough, dyspnea, dry/wet sound of lung and hospitalization time in the observation group were shorter than those in the control group (P<0.05). There was no significant difference in T lymphocyte subsets and immunoglobulin levels between the two groups before treatment (P>0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+, immunoglobulin A (IgA) and immunoglobulin G (IgG) in the observation group were significantly higher than those in the control group, and the levels of CD8+ and immunoglobulin E (IgE) were significantly lower than those in the control group(P<0.05). Before treatment, there were no significant differences between the two groups in the levels of interleukin-4 (IL-4), IL-23, and eosinophil cationic protein (ECP) (P>0.05). After treatment, the levels of IL-4, IL-23 and ECP in the observation group were significantly lower in the group than in the control group (P<0.05).【Conclusion】Glucocorticoid therapy in children with bronchitis can promote the disappearance of clinical symptoms and signs, improve the immune function of children, inhibit the expression levels of serum IL-4,IL-23,ECP, and shorten hospitalization time.
|
|
Received: 16 November 2018
|
|
|
|
|
|
[1] 智玉萍,何学明,董青.婴幼儿毛细支气管炎发展为哮喘的免疫机制研究进展[J].中国儿童保健杂志,2017,25(10):1027-1029,1033.
[2] 郑小萍,唐莉.盐酸氨溴索与布地奈德单用或联合雾化吸入辅助治疗小儿毛细支气管炎疗效比较[J].儿科药学杂志,2017,23(9):23-25.
[3] 孙琦玮,曲政海,王冲,等.吸入型糖皮质激素治疗婴幼儿喘息性支气管炎疗效对比研究[J].中国医师进修杂志,2016,39(6):500-503.
[4] 罗伟冰.布地奈德雾化吸入联合舒利迭治疗COPD合并感染患者疗效观察[J].内科,2016,11(1):100-102.
[5] 胡亚美,江载芳.诸福堂实用儿科学[M].第7版.北京:人民卫生出版社,2002:1172-1200.
[6] 李红菊,姜翠英.毛细支气管炎患儿外周血IL-4、IL-17、IP-10、IgE的水平变化及意义[J].中国妇幼保健,2017,32(17):4168-4170.
[7] 吴祖成,林世光,鄢能荣,等.家庭雾化吸入治疗毛细支气管炎85 例可行性分析[J].儿科药学杂志,2017,23(10):14-16.
[8] Hirahara K,Nakayama A T.CD4+ T cell subsets in inflamatory diseases beyond the Thl/Th2 paradigm[J].Int Immunol,2016,28(4):163-165.
[9] 邓亚军.孟鲁司特钠咀嚼片联合维生素K3注射液治疗小儿毛细支气管炎的临床疗效及IL-4、IL-10、IgE水平变化[J].中国妇幼保健,2017,32(7):1479-1481.
[10] 姜红,侯丽洁.孟鲁司特对毛细支气管炎患儿IL-17和IL-23表达的影响以及临床疗效分析[J].临床肺科杂志,2016,21(6):1021-1023.
[11] 李益.反复喘息婴幼儿血清25-OH-D3、干扰素-γ及IL-4,IL-13水平及相关性研究[J].哈尔滨医药,2016,36(1):26-28.
[12] 王叶芳,崔倪,诸葛远莉,等.布地奈德雾化吸入对毛细支气管炎患儿血清IL-4、INF-γ、TNF-α及T淋巴细胞亚群的影响[J].现代生物医学进展,2017,17(32):6271-6274. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(8): 1539-1541. |
|
|
|
|
2019, Vol. 36 
